Literature DB >> 1723682

The 'Sicilian Gambit'. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.

.   

Abstract

The Queen's Gambit is an opening move in chess that provides a variety of aggressive options to the player electing it. This report represents a similar gambit (the 'Sicilian Gambit') on the part of a group of basic and clinical investigators who met in Taormina, Sicily, to consider the classification of antiarrhythmic drugs. Paramount to their considerations were (1) dissatisfaction with the options offered by existing classification systems for inspiring and directing research, development and therapy, (2) the disarray in the field of antiarrhythmic drug development and testing in this post-CAST era, and (3) the desire to provide an operational framework for consideration of antiarrhythmic drugs that will both encourage advancement and have the plasticity to grow as a result of the advances that occur. The multifaceted approach suggested is, like the title of the manuscript, a gambit. It is an opening rather than a compendium, and is intended to challenge thought and investigation rather than to resolve issues. The manuscript incorporates first, a discussion of the shortcomings of the present system for drug classification; second, a review of the molecular targets on which drugs act (including channels and receptors); third, a consideration of the mechanisms responsible for arrhythmias, including the identification of 'vulnerable parameters' that might be most accessible to drug effect; and finally, clinical considerations with respect to antiarrhythmic drugs. Information relating to the various levels of information is correlated across categories (i.e., clinical arrhythmias, cellular mechanisms and molecular targets), and a 'spread sheet' approach to antiarrhythmic action is presented that considers each drug as a unit, with similarities to and dissimilarities from other drugs being highlighted. A complete reference list for this work would require as many pages as the text itself. For this reason, referencing is selective and incomplete. It is designed, in fact, to provide sufficient background information to give the interested reader a starting frame of reference, rather than to recognize the complete body of literature that is the basis for this paper.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723682

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

Review 1.  Cardiac sympathetic denervation to prevent life-threatening arrhythmias.

Authors:  Peter J Schwartz
Journal:  Nat Rev Cardiol       Date:  2014-03-11       Impact factor: 32.419

Review 2.  Investigational antiarrhythmic agents: promising drugs in early clinical development.

Authors:  Jordi Heijman; Shokoufeh Ghezelbash; Dobromir Dobrev
Journal:  Expert Opin Investig Drugs       Date:  2017-07-20       Impact factor: 6.206

Review 3.  Pharmacological modulation of connexin-formed channels in cardiac pathophysiology.

Authors:  Elke De Vuyst; Kerstin Boengler; Gudrun Antoons; Karin R Sipido; Rainer Schulz; Luc Leybaert
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 4.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

5.  The medical management of pediatric arrhythmias.

Authors:  Carolina Escudero; Roxane Carr; Shubhayan Sanatani
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-10

Review 6.  Multiscale Modeling in the Clinic: Drug Design and Development.

Authors:  Colleen E Clancy; Gary An; William R Cannon; Yaling Liu; Elebeoba E May; Peter Ortoleva; Aleksander S Popel; James P Sluka; Jing Su; Paolo Vicini; Xiaobo Zhou; David M Eckmann
Journal:  Ann Biomed Eng       Date:  2016-02-17       Impact factor: 3.934

Review 7.  Cardiac physiology and clinical efficacy of dietary fish oil clarified through cellular mechanisms of omega-3 polyunsaturated fatty acids.

Authors:  Peter L McLennan
Journal:  Eur J Appl Physiol       Date:  2014-04-04       Impact factor: 3.078

Review 8.  Optimal treatment after acute myocardial infarction in the elderly.

Authors:  J Herlitz; M Hartford; M Dellborg; B W Karlson
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

Review 9.  A clinical approach to arrhythmias revisited in 2018 : From ECG over noninvasive and invasive electrophysiology to advanced imaging.

Authors:  L Jordaens
Journal:  Neth Heart J       Date:  2018-04       Impact factor: 2.380

Review 10.  Antiarrhythmic drugs for atrial fibrillation: Imminent impulses are emerging.

Authors:  Gheorghe-Andrei Dan; Dobromir Dobrev
Journal:  Int J Cardiol Heart Vasc       Date:  2018-09-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.